Intra-Cellular Therapies Submits Supplemental New Drug Application for CAPLYTA
On December 3, 2024, Intra-Cellular Therapies, Inc. (NASDAQ: ITCI) announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration for CAPLYTA (lumateperone) for the treatment of Major Depressive Disorder (MDD) as adjunctive therapy to antidepressants. This submission follows positive results from Studies 501 and 502, showcasing CAPLYTA’s robust […]
More Stories
Upcoming Korean Drama: 100 Days of Deception Release Date, Plot, and More
K-drama fans have been longing for a historical action-romance series. Are you also one of those fans who are desperately...
Custom Web Application Development Process: Benefits, Example, Process, and Cost
For a developing business, it sometimes becomes difficult to manage spreadsheets, teams, and SaaS tools. Are you also facing the...
Netflix’s Upcoming Documentary: A Child of My Own Release Date and More
Are you also interested in watching the real-life documentary? If yes, then this blog is for you. One of the...
Announcement! 1670 Season 4 is Releasing Soon! Release Date, Trailer Updates, and More
Hello! Polish TV series and movie fans. 1670 is going to end soon. With great reviews and huge viewership, the...
Semrush vs Serpstat vs Ahrefs: Which Is Better?
No business today can skip search engine optimization if they want to lead in the online marketplace. From keyword research...
Murder in a Small Town Season 3 Is Releasing Soon on Netflix
Murder in a Small Town Season 3 is coming back with an-all-new drama and suspenseful storyline for its viewers. The...